maliqun61 schreef op 10 november 2017 12:57:
[...]
Staat toch in dat rapport op pagina 2:
PRICE TARGET CALCULATION
We value Ruconest in hereditary angioedema (HAE) at €2.90/share, applying a 7x multiple to estimated 2022 WW sales of €620M,discounted 25% annually. Cash makes up the remaining €0.10/share of our €3.00 price target.